Stifel notes that positive Phase 1/2 GALILEO-1 update lifted Freeline shares on Wednesday morning. Setting aside past disappointments, the FLT201 update is nothing short of promising for the company and its AAVS3 delivery vector, the firm says. Despite rise in share price, Stifel can’t dismiss Freeline’s current financial strength that, given a fairly light catalyst calendar, could lead to dilution near-term. The firm keeps a Hold rating on the shares with a price target of $4.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FRLN:
- Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
- Freeline reports initial data from first cohort of Phase 1/2 GALILEO-1 trial
- Freeline price target raised to $4 from $3 at Stifel
- Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
- Freeline expects initial clinical data from GALILEO-1 trial in Q3
